Silo Pharma enters agreement with Frontage Laboratories for SPC-15 study

Silo Pharma (SILO) has entered into an agreement with Frontage Laboratories for a Food and Drug Administration requested 7-day safety and toxicology large animal study of its lead asset SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder. The Company is currently working on a separate IND-enabling Good Laboratory Practice-compliant toxicology and toxicokinetic study of SPC-15. Positive preclinical data from these studies, if achieved, would support an IND submission for SPC-15 in 2025. Should Silo receive approval of the IND, Silo would proceed to a first-in-human Phase 1 clinical trial for SPC-15. Columbia University, the Company’s collaboration partner for pre-clinical development, granted Silo an exclusive global license to further develop, manufacture, and commercialize SPC-15 worldwide.